Nursing Homes—Insight into A Network of Microbial Resistance


A new study pulls back the curtain into a complex web of resistance, colonization, and the challenges of antimicrobial resistance in this setting.

Antimicrobial resistance is one of the most complex and challenging infectious disease threats we face. Combatting resistant organisms isn’t just a matter of addressing prescribing habits, but also understanding the interconnectedness of treatment, colonization, infection, transmission, etc. These factors work together to facilitate antimicrobial resistance and it is crucial that response efforts to this threat are just as diverse.

The Centers for Disease Control and Prevention (CDC) estimates that roughly 2 million people are infected with drug-resistant bacteria in the United States, each year. The cost to the US health system for these infections is between $21 and 34 billion dollars, annually, which makes the burden of microbial resistance not only significant in terms of morbidity and mortality but also economically.

A recent study sought to address the interaction between resistant organisms and antibiotics to gain a better hold on what needs to be done to overcome them. The best part? The researchers addressed nursing homes, which are hubs for microbial resistance.

Assessing data across 234 residents within 12 nursing homes, they looked at antibiotic usage, colonization (the first stage of microbial infection, in which the organism is detectable within the body, but not causing signs or symptoms of infection) with multidrug-resistant organisms (MDROs), and actual infections. The mean age of patients was about 74 years old, and the researchers addressed the prevalence of MDROs in the groin and perirectum, finding that the most common MDROs colonizing that region were vancomycin-resistant Enterococci (VRE) (30.3%), Methicillin-resistant Staphylococcus aureus (MRSA) (29.9%), and resistant Gram-negative bacteria (like E. coli, Proteus mirabilis, and Acinetobacter baumannii). They also found that a majority of residents were colonized with 1 species, but that a fair amount were colonized with 2 or 3 species of MDROs.

A total of 62% of residents had also received at least 1 course of antibiotic treatment. The researchers established that antibiotic use was a risk factor for primary colonization with a MDRO, which also increased the likelihood of colonization for a secondary or tertiary MDRO.

“We observed that multiple antibiotics could be associated with the acquisition of a single MDRO. Conversely, a single antibiotic could be associated with acquiring multiple MDRO species; for example, aminoglycosides increased the risk of acquiring VRE, A. baumannii, E. coli, P. mirabilis, and P. aeruginosa,” stated the authors.

They also found that colonization was associated with an increased risk of having a catheter-associated urinary tract infection, noting that the “bacterial network shows that the effects of antibiotic exposure contribute to colonization as well as disease, potentially mediated by synergistic interactions between colonizing MDROs.”

What does this mean for antimicrobial resistance and stewardship? Ultimately, the researchers highlighted the complexity and inter-workings of MDROs, antibiotics, and that patient colonization and infection can all be influenced by these components. It is particularly interesting that they found such a high prevalence of antibiotic usage and that so many patients were colonized with a MDRO. This study is also highly relevant in that it highlights the linkage between MDRO colonization and antibiotic exposure, as well as colonization with a secondary MDRO.

The interconnectedness of antibiotic exposure, MDRO colonization, and risk for additional MDROs, all draws attention the complexity of these environments and antimicrobial resistance. Not only are patients at an increased risk for colonization following antibiotic exposure, but this also makes them more likely to become colonized with a secondary MDRO. The authors point to the need for providers and further stewardship efforts to consider this close network of risk factors and exposures, especially in long-term care facilities.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.